CLSD Company Profile and Key Details

CLSD has shown weak momentum, losing -84.29% over the past week and -92.56% over the past quarter, though year-to-date performance is down -97.12%. Short-term trend indicators are bullishly aligned (SMA20 -86.23%, SMA50 -88.61%, SMA200 -95.46%). The stock’s 14-day RSI is 16.06 (weak momentum), while the ATR of 0.4 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -97.6% below its high and over 10.78% above its low.

Clearside Biomedical, Inc. generated EPS of -$5.06 over the past year. Five-year average earnings growth is 10.4%. Wall Street analysts project EPS growth of 22.36% annually over the next five years. The latest quarter delivered EPS of -$1.14. The next quarter is forecast at -$0.60. Next year's EPS is expected at -$7.14. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 6 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $3.00. The high target offers 500.0% upside. The low target suggests 200.0% downside. The mean target is $5.00. This offers 400.0% upside. Clearside Biomedical, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 14, 2025, missed forecasts by 70.15%. The prior quarter beat by -50.0%. Over the last six quarters, Apple has recorded several small beats. These include -28.57% in August 12, 2024.

Clearside Biomedical, Inc. (NASDAQ:CLSD) closed at $1.00 USD, losing -$0.04 (-3.85%) from the previous close of $1.04. The stock is currently mid-range between its 52-week high and low $0.37 and $17.10. With a market capitalization of about $5.23 million, Clearside Biomedical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.79). Key stats such as the average daily volume over the past year has been around 265.60 thousand shares, volume is running light vs its 52-week average. Headquartered in Alpharetta, GA, Clearside Biomedical, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO George Lasezkay, the company employs approximately 32 people and listed since June 02, 2016. Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.

Clearside Biomedical, Inc. has 78.51 million shares outstanding. The public float is 4.54 million shares, elevated short interest at 0.15% of float. This equals 114.66 thousand shares. The short ratio is 2.31 days. Institutional investors hold 17.07% of the float. Insiders own 12.88%. White Daniel H. holds 483.34 thousand shares, LASEZKAY GEORGE M has 466.58 thousand shares and WHITMORE BRADFORD T has 444.44 thousand shares.

Our AI price prediction model suggests that Clearside Biomedical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by December 12, 2025, within a range of $0.00 to $0.52 3-Month Outlook: Projected fall of -85.37%, reaching $0.06 by February 26, 2026, with a range of $0.00 to $0.56. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by November 27, 2026, within a range of $0.00 to $0.69.

Clearside Biomedical, Inc. (NASDAQ:CLSD) shares are down -97.12% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Clearside Biomedical, Inc. trading at a premium to the broader market with a P/E of -0.19. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $7.56, suggesting 1743.9% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-85.37% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Clearside Biomedical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.05. This means the shares are trading near this model’s fair value.

Clearside Biomedical, Inc. trades at a P/E ratio of -0.19, slightly below the S&P 500 average, with a price-to-sales ratio of 1.26 and a price-to-book ratio of -0.11 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.24, also below market averages.